Annual report
4521.TEDINET S100YK2Q
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥76.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥94.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥72.0bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥73.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥76.0bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | −¥899m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥21.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | −¥206m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥21.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.0bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.3bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥19.4bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥8.0bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.4bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥13.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥178.2bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥193.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥171.6bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥166.3bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥165.2bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥30.6bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥40.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥147.6bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥152.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥143.8bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥136.8bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥138.3bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥44.7bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥54.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥50.7bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥70.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥65.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥74.3bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥74.6bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥11.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥29.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥9.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥13.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥315m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥19.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.9bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.9bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥8.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥56.57 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥365.42 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥212.67 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥144.8 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥251.43 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,898.24 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,974.47 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,796.05 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,636.17 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,642.34 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 82.8% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.8% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.9% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 1.4% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.0% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,114 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 1,126 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,135 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 1,130 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 1,164 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥72.3bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥93.9bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥72.0bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥72.9bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥75.9bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | −¥694m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥22.5bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | −¥112m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥22.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥10.2bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.9bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.9bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.3bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥22.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.0bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥16.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥8.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.8bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.9bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥172.1bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥189.5bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥168.9bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥163.7bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥161.8bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥25.0bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥36.0bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥147.2bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥153.5bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥143.3bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥136.6bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥136.6bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥37.9bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥49.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥51.84 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥431.06 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥224.79 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥180.07 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥260.61 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥190 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥190 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,886.35 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,996.6 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,784.55 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,644.33 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,611.75 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 85.5% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.9% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.4% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.3% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 44,139,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,086 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 1,103 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 1,124 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 1,117 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 1,152 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥62.6bn |
| Medicinereportable segment | capex | 2025-04-01 → 2026-03-31 | ¥6.2bn |
| Medicinereportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥3.4bn |
| Medicinereportable segment | employees | at 2026-03-31 | 1113 pure |
| Medicinereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥74.3bn |
| Medicinereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥74.3bn |
| Medicinereportable segment | segment assets | at 2026-03-31 | ¥106.2bn |
| Medicinereportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥2.3bn |
| Real Estatereportable segment | capex | 2025-04-01 → 2026-03-31 | ¥9m |
| Real Estatereportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥361m |
| Real Estatereportable segment | employees | at 2026-03-31 | 1 pure |
| Real Estatereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.5bn |
| Real Estatereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.5bn |
| Real Estatereportable segment | segment assets | at 2026-03-31 | ¥9.4bn |
| Real Estatereportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥76.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥76.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥115.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | −¥899m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥78.9bn |
| Medicinereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥20.2bn |
| Medicinereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.1bn |
| Medicinereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥91.6bn |
| Medicinereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥91.6bn |
| Medicinereportable segment | segment assets | at 2025-03-31 | ¥103.2bn |
| Medicinereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥19.7bn |
| Real Estatereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥56m |
| Real Estatereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥340m |
| Real Estatereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Real Estatereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Real Estatereportable segment | segment assets | at 2025-03-31 | ¥11.3bn |
| Real Estatereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥20.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥94.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥94.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥114.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥21.0bn |
| Medicinereportable segment | employees | at 2026-03-31 | 1085 pure |
| Real Estatereportable segment | employees | at 2026-03-31 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,738
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 94035000000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YearDuration | 94035000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 19659000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 1375000000 | JPY |
| Operating income | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 21034000000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YearDuration | 21034000000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 103175000000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 11285000000 | JPY |
| Assets | Prior1YearInstant_TotalOfReportableSegmentsAndOthersMember | 114460000000 | JPY |
| Assets | Prior1YearInstant_ReconcilingItemsMember | 78916000000 | JPY |
| Assets | Prior1YearInstant | 193377000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 3086000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 340000000 | JPY |
| Depreciation segment information | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 3426000000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Depreciation segment information | Prior1YearDuration | 3426000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 79000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 79000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 79000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 20225000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 56000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 20281000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration | 20281000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 72547000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 72547000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Net sales of finished goods and merchandise | CurrentYearDuration | 72547000000 | JPY |
| Royalty | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 1781000000 | JPY |
| Royalty | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Royalty | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 1781000000 | JPY |
| Royalty | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Royalty | CurrentYearDuration | 1781000000 | JPY |
| Other income | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | － | JPY |
| Other income | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 2543000000 | JPY |
| Other income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 2543000000 | JPY |
| Other income | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Other income | CurrentYearDuration | 2543000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | 74328000000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | 2543000000 | JPY |
| Revenues from external customers | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 76871000000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 76871000000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00935-000MedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E00935-000RealEstateReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |